Approval · Notice of Compliance 17166 · 2015
REQUIP: Notice of Compliance 17166
Issued August 4, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17166
- Date
- August 4, 2015
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of all references to the 0.5 mg, 3.0 mg and 4.0 mg tablet representations from the product monograph
- Therapeutic class
- Antiparkinsonian agent, dopamine agonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REQUIP | Not yet assigned | — |
Medicinal ingredients
- ROPINIROLE HYDROCHLORIDE 0.25 MG per TAB
- ROPINIROLE HYDROCHLORIDE 0.5 MG per TAB
- ROPINIROLE HYDROCHLORIDE 1 MG per TAB
- ROPINIROLE HYDROCHLORIDE 2 MG per TAB
- ROPINIROLE HYDROCHLORIDE 3 MG per TAB
- ROPINIROLE HYDROCHLORIDE 4 MG per TAB
- ROPINIROLE HYDROCHLORIDE 5 MG per TAB